Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

CAMBRIDGE, England, March 20, 2012 /PRNewswire/ --

XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally. The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and demonstrated good pharmacokinetic (PK) properties. The results support the continuing development of XEN-D0103 for the treatment of atrial fibrillation (AF), a commonly encountered and potentially serious cardiac arrhythmia in which the atria of the heart beat in a rapid and irregular manner, resulting in reduced cardiac output and increased risk of stroke.

The phase 1 clinical trial, which was conducted in the UK, studied single and multiple ascending oral doses of XEN-D0103 in healthy volunteer subjects in three parts. The study evaluated the safety and pharmacokinetics of various doses and also the effects of food. XEN-D0103 was well tolerated with a good PK profile and no significant food, gender or age related effects were observed. No significant adverse events were reported.

Importantly, a detailed ECG (electrocardiogram) analysis of data collected from the first cohort of 30 healthy volunteers indicated that XEN-D0103 had no effect on the QTcF interval. This absence of any detectable effect on QTcF, confirming the atrial selectivity of XEN-D0103, is an important safety attribute for a new atrial fibrillation drug, since many current antiarrhythmic drugs can lead to significant QT-interval prolongation and further arrhythmia problems.

Tim Brears, Chief Executive Officer of Xention commented, "We are very pleased to report these positive phase 1 data, specifically the observations that XEN-D0103 may have a much safer profile than current antiarrhythmic dru
'/>"/>

SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... researchers from the University of Leicester has furthered ... the potential to create new materials using nanosized ... published in the prestigious academic journal Physical ... to examine in rich detail the structure and ... an acetylene molecule and a single helium atom. ...
(Date:7/25/2014)... July 25, 2014 WABC Radio show out ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s ... stem cell therapy in pets. Dr. Harman first visited ... stem cell therapy for pets suffering from osteoarthritis and other ... Veterinary Medicine industry forward. , Young has invited Dr. Harman ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... the Harvard Business Review (HBR), containing an ... , questioned the impact of IT investments. This has ... One of the dissenters of Carrs article is PRISM ... specializes in Outsourced Marketing Services and uses technology to ...
... eFilm to offer an integrated PAC (picture achieving and ... target market of hospitals and imaging centers. , ... milestone in our evolution as a healthcare software and ... our target market," said Rich Linden, Merge eFilm president ...
... Ill. Though electricity and telephones dont even exist at ... the next highly underserved segment to be wired by ... Monday. Motorola says Indian reservations could be the most ... ,When identifying the need for high-speed Internet access for ...
Cached Biology Technology:IT Does Matter! 2IT Does Matter! 3Merge eFilm to buy Ohio firm in $14M Deal 2Merge eFilm to buy Ohio firm in $14M Deal 3Motorola Canopy Wires Indian Reservations 2
(Date:7/27/2014)... that wiped them out if it had taken place ... A fresh study using up-to-date fossil records and improved ... narrative of the prehistoric creatures, demise, some 66 million ... million years before a 10km-wide asteroid struck what is ... extensive volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... N.C. -- Microorganisms like bacteria and fungi can evade ... antibiotics or antifungal drugs. These permanent mutations were once ... to evolve. Now a new study has shown that ... -- known as epimutations -- to gain the benefits ... new mechanism was discovered in a fungus called Mucor ...
(Date:7/27/2014)... of "big data," a single computer cannot always find ... be distributed across a cluster of computers that analyze ... Google mine your web history to present you with ... next favorite book or movie. But big data is ... for monitoring brain activity are generating unprecedented quantities of ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... University is now giving forensic scientists a tool that can ... may contribute to resolving missing-persons cases, among other uses. Identifying ... but traditionally it has been exceptionally difficult to identify the ... research is that children,s faces attain the shapes they will ...
... Researchers at the Santa Fe Institute have developed new ... PLOS Computational Biology on May 13. Quantitative ... the logic of conflict. Game theory seeks to identify normative ... uncertainty. Although game theory has been very useful for ...
... to glimpse into the future of their health? On ... (NHGRI) and the National Cancer Institute (NCI), along with Group ... debate and discuss that question during the one-day symposium "Multiplex ... to attend the symposium. It will be held from 7:30 ...
Cached Biology News:New forensics research will help identify remains of children 2Game theoretic machine learning methods can help explain long periods of conflict 2Symposium: Implications for the future of personalize medicine 2Symposium: Implications for the future of personalize medicine 3
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: